The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

L B Ramsey¹, S G Johnson², K E Caudle¹, C E Haidar¹, D Voora³, R A Wilke⁴, W D Maxwell⁵, H L McLeod⁶, R M Krauss⁷, D M Roden⁸, Q Feng⁸, R M Cooper-DeHoff⁹, L Gong¹⁰, T E Klein¹⁰, M Wadelius¹¹, M Niemi¹²

Affiliations

¹ Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
² 1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
³ Department of Medicine, Duke University, Durham, North Carolina, USA.
⁴ 1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
⁵ Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
⁶ Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
⁷ Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
⁸ 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
⁹ Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
¹⁰ Department of Genetics, Stanford University, Palo Alto, California, USA.
¹¹ Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
¹² 1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.

PMID: 24918167
PMCID: PMC4169720
DOI: 10.1038/clpt.2014.125

Practice Guideline

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

L B Ramsey et al. Clin Pharmacol Ther. 2014 Oct.

. 2014 Oct;96(4):423-8.

doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.

Authors

Affiliations

¹ Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
² 1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
³ Department of Medicine, Duke University, Durham, North Carolina, USA.
⁴ 1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
⁵ Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
⁶ Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
⁷ Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
⁸ 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
⁹ Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
¹⁰ Department of Genetics, Stanford University, Palo Alto, California, USA.
¹¹ Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
¹² 1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.

PMID: 24918167
PMCID: PMC4169720
DOI: 10.1038/clpt.2014.125

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

Trial registration: ClinicalTrials.gov NCT01894230.

PubMed Disclaimer

References

1. Wilke R.A., et al. Clinical Pharmacogenomics Implementation Consortium (CPIC) The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 2012;92:112–117. - PMC - PubMed
1. Wilke R.A., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 2007;6:904–916. - PMC - PubMed
1. Buettner C., Rippberger M.J., Smith J.K., Leveille S.G., Davis R.B., Mittleman M.A. Statin use and musculoskeletal pain among adults with and without arthritis. Am. J. Med. 2012;125:176–182. - PMC - PubMed
1. Wilke R.A., Dolan M.E. Genetics and variable drug response. JAMA. 2011;306:306–307. - PMC - PubMed
1. Ramsey L.B., et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22:1–8. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

Affiliations

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical